Iterum Therapeutics (ITRM) shares gained more than 36% in recent Friday trading after the company said the US Food and Drug Administration has approved its new drug application for Orlynvah as a treatment for uncomplicated urinary tract infections in women.
The approval was based on data from its clinical development program, including the results from two phase 3 trials where Orlynvah demonstrated "superiority" to other treatments, the company said.
Iterum said the approval marks the first indication for Orlynvah, making it the company's first FDA-approved product.
Price: 1.99, Change: +0.82, Percent Change: +70.09
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。